We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Stem Cell and CRISPR Technologies Combine to Study Mutant Tau Genes

By LabMedica International staff writers
Posted on 25 Dec 2018
Print article
Image: The photomicrograph shows neurons (red) with a mutation in the MAPT gene - a gene that makes the protein tau. People with this mutation develop frontotemporal dementia. Researchers found that cells carrying the MAPT mutation developed abnormalities in genes that control communication between the brain cells (Photo courtesy of Sidhartha Mahali, Washington University School of Medicine).
Image: The photomicrograph shows neurons (red) with a mutation in the MAPT gene - a gene that makes the protein tau. People with this mutation develop frontotemporal dementia. Researchers found that cells carrying the MAPT mutation developed abnormalities in genes that control communication between the brain cells (Photo courtesy of Sidhartha Mahali, Washington University School of Medicine).
A mutant form of the gene coding for tau protein contributes to the development of frontotemporal dementia by reducing the expression of GABA (gamma-aminobutyric acid) receptor genes in the brain.

Frontotemporal dementia, which accounts for about 20% of all cases of early-onset dementia, tends to afflict people with memory loss from the age of 40 to the early 60s. Previous studies have shown that mutations in the microtubule-associated protein tau (MAPT) gene cause autosomal dominant frontotemporal lobar degeneration with tau inclusions (FTLD-tau). Individuals carrying the MAPT p.R406W mutation present clinically with progressive memory loss and neuropathologically with neuronal and glial tauopathy. However, the pathogenic events triggered by the expression of the mutant tau protein remain poorly understood.

To determine how mutant tau protein causes memory loss, investigators at Washington University School of Medicine (St, Louis, MO, USA) used a combination of stem cell technology and CRISPR/cas9 gene editing.

The investigators prepared neurons with the MAPT mutation that had been derived from induced pluripotent stem cells (iPSCs) generated from skin cells obtained from FTLD-tau patients. CRISPR/Cas9 gene editing was used to eliminate the mutation in some neurons but not in others (isogeneic controls).

The investigators reported in the December 13, 2018, online edition of the journal Translational Psychiatry that the expression of the MAPT p.R406W mutation was sufficient to create a significantly different transcriptomic profile compared with that of the isogeneic controls and to cause the differential expression of 328 genes. Sixty-one of these genes were also differentially expressed in the same direction between MAPT p.R406W carriers and pathology-free human control brains.

Genes differentially expressed in the stem cell models and human brains were enriched for pathways involving gamma-aminobutyric acid (GABA) receptors and pre-synaptic function. The expression of GABA receptor genes, including GABRB2 and GABRG2, were consistently reduced in iPSC-derived neurons and brains from MAPT p.R406W carriers. In addition, GABA receptor genes, including GABRB2 and GABRG2, are significantly lower in symptomatic mouse models of tauopathy. Genome wide association analyses reveal that common variants within GABRB2 were associated with increased risk for frontotemporal dementia.

The investigators suggested that by demonstrating that MAPT p.R406W was sufficient to induce changes in GABA-mediated signaling and synaptic function, which may contribute to the pathogenesis of FTLD-tau and other primary tauopathies, they had confirmed a systems biology approach, which leveraged molecular data from stem cells, animal models, and human brain tissue to reveal novel disease mechanisms.

"We have demonstrated that we can capture changes in human cells cultured in a dish that also are appearing in the brains of individuals suffering with frontotemporal dementia," said senior author Dr. Celeste M. Karch, assistant professor of psychiatry at Washington University School of Medicine. "Importantly, the approach we are using allows us to zero in on genes and pathways that are altered in cells and in patient brains that may be influenced by compounds already approved by the FDA. We want to evaluate whether any of these compounds could prevent memory loss, or even restore memory, in people with frontotemporal dementia by improving the function of these pathways that have been disrupted."

Related Links:
Washington University School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.